FDA 483 - Catalent Belgium SA

An FDA inspection of Catalent Belgium SA revealed significant deficiencies in their manufacturing processes for sterile drug products. Observations included a lack of established procedures for handling media fill failures, inadequate adherence to good documentation practices by the quality control unit, and insufficient controls over computer systems allowing unauthorized data manipulation. Additionally, the firm failed to establish the accuracy and reproducibility of certain analytical test methods.